Treatment for childhood leukemia is mainly multi-drug chemotherapy given in planned phases over months to years. Targeted drugs, immunotherapy, and stem cell transplant are added for higher-risk or relapsed cases. Results have improved steadily over the decades, and most children with the commonest type, acute lymphoblastic leukemia, are now cured. Here I explain how treatment is structured, how it is tailored to each child, and where research is heading.
What Is Childhood Leukemia?
Leukemia is the most common cancer in children and a large part of pediatric oncology. It begins in the bone marrow, where an immature blood cell gains genetic changes that make it multiply without maturing.
These leukemic cells are abnormal white blood cells that crowd out healthy ones. As a result, the marrow cannot make enough red cells to carry oxygen, platelets to stop bleeding, or normal white cells to fight infection. The underlying genetic errors disrupt normal blood cell development by switching on growth genes or switching off genes that normally hold cell division in check.
Main Types
The two main types of childhood leukemia are acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). ALL accounts for roughly three-quarters of cases and peaks in early childhood. AML is less common and generally needs more intensive treatment. Chronic leukemias are rare in children.
Signs, Risk Factors, and Diagnosis
Most symptoms come from bone marrow failure: tiredness and pallor from anemia, bruising or nosebleeds from low platelets, and repeated infections or fevers. Children may also have bone or joint pain, swollen lymph nodes, an enlarged liver or spleen, and sometimes involvement of the central nervous system.
In most children no cause is found. Known risk factors include Down syndrome, some inherited marrow failure and cancer predisposition syndromes, and previous high-dose radiation or chemotherapy. Leukemia is not caused by anything parents did or failed to do.
The path to a diagnosis of leukemia starts with a complete blood count and blood smear. Children with abnormal blood results then have a bone marrow test, which remains the gold standard for leukemia diagnosis. Flow cytometry, cytogenetics, and molecular tests identify the exact subtype and genetic features, and a lumbar puncture checks whether leukemia cells are in the spinal fluid.
How the Treatment for Childhood Leukemia Is Structured
Children are usually treated on standardized protocols at specialist pediatric centers. Each child is assigned a risk group based on age, white cell count at diagnosis, leukemia genetics, and, most importantly, how quickly the leukemia responds. You can compare the broader range of treatment for childhood leukemia and adult leukemia options in our dedicated guide.
For ALL, treatment typically runs through the following phases:
| Phase | Purpose | What it involves |
|---|---|---|
| Induction | Achieve remission | Several chemotherapy drugs plus a steroid, over about four to five weeks |
| Consolidation | Kill remaining leukemia cells | Further chemotherapy, intensity set by risk group |
| Delayed intensification | Reduce relapse risk | A repeat burst of intensive treatment |
| Maintenance | Keep leukemia from returning | Mostly oral chemotherapy at home, lasting until about two to three years of total treatment |
| CNS-directed therapy | Prevent spread to brain and spinal fluid | Chemotherapy injected into the spinal fluid throughout treatment |
AML in children is treated with shorter but more intensive chemotherapy courses, usually four or five cycles in hospital. Children with high-risk AML may proceed to a stem cell transplant.
Measuring Response
Measurable residual disease (MRD) testing looks for tiny numbers of leukemia cells that a microscope would miss. MRD results at the end of induction are among the most powerful guides to treatment. Children who clear the disease quickly can often avoid the most intensive therapy, while those with persistent MRD receive more.
Targeted Therapy, Immunotherapy, and Transplant
Several newer treatments now sit alongside chemotherapy:
- Tyrosine kinase inhibitors such as imatinib or dasatinib are added for Philadelphia chromosome-positive ALL.
- Blinatumomab, a bispecific T-cell engager, directs the child’s own T-cells against B-cell ALL and is used for relapsed disease and increasingly earlier in treatment.
- Inotuzumab ozogamicin, an antibody carrying a toxin, targets the CD22 marker on B-ALL cells.
- CAR T-cell therapy (tisagenlecleucel) reprograms a child’s T-cells to attack CD19-positive leukemia in relapsed or refractory B-cell ALL.
- Allogeneic stem cell transplant, sometimes with total body irradiation, is reserved for very high-risk or relapsed disease.
Advancing Treatment: Research and Long-Term Care
Much current research aims to cure more children with less harm. Detailed genetic profiling is revealing new subtypes, such as Ph-like ALL, that may respond to targeted drugs. Trials are testing whether immunotherapy can replace some of the most toxic chemotherapy, and whether children with very good MRD responses can safely receive less treatment.
Survivorship care is part of the job too. Some treatments can affect growth, fertility, heart function, bone health, or learning, so children are followed into adulthood. We cover more of these new frontiers in childhood leukemia treatment elsewhere, along with how leukemia care is advancing from diagnosis to advanced treatment more broadly.
When to See a Doctor
See your child’s doctor promptly if they have unexplained pallor or tiredness, bruising or tiny red spots on the skin, frequent or prolonged fevers, persistent bone pain or limping, or swollen glands that do not settle. These symptoms usually have common, harmless causes, but a simple blood count can rule out leukemia. During treatment, any fever needs urgent contact with the oncology team.
Frequently Asked Questions
Is childhood leukemia curable?
Yes. Most children with ALL are cured with current protocols, and outcomes for AML have improved too, though they remain lower than for ALL. The outlook depends on the subtype, genetics, and response to early treatment.
How long does treatment last?
ALL treatment typically lasts about two to three years in total, with the most intensive part in the first several months. AML treatment is shorter, usually around six months of intensive chemotherapy, unless a transplant is needed.
Can my child go to school during treatment?
During maintenance, many children return to school and normal activities with some precautions. During intensive phases, time off is often needed because of infection risk. Your care team will advise based on your child’s blood counts.
Did something we did cause the leukemia?
No. In almost all cases, childhood leukemia arises from random genetic changes in developing blood cells. It is not caused by diet, parenting, or anything that could reasonably have been prevented.
